DPP9 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human NCI-H1975 lung adenocarcinoma cell line. This product features targeted disruption of the DPP9 gene, resulting in a loss-of-function model suitable for investigating DPP9-dependent cellular processes. The polyclonal format provides a heterogeneous knockout pool, reflecting diverse editing outcomes across the cell population, and is ideal for studies where selection of single-cell clones is not required. The cells are provided as a ready-to-use resource for functional genomics, drug target validation, and pathway analysis in cancer biology.
The parental NCI-H1975 cell line is a widely used model of EGFR-mutant non-small cell lung cancer (NSCLC) harboring the T790M resistance mutation. Derived from a female patient with lung adenocarcinoma, these epithelial cells exhibit constitutive EGFR signaling and are employed extensively to study mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). The NCI-H1975 background offers a clinically relevant context for exploring how DPP9 loss influences tumor cell behavior, particularly in the setting of oncogenic EGFR addiction.
DPP9 encodes an intracellular serine protease that cleaves N-terminal dipeptides with Pro or Ala at the penultimate position. It functions as a key negative regulator of the NLRP1 inflammasome, maintaining NLRP1 in an inactive state and preventing caspase-1 (CASP1) activation and subsequent IL-1?? (IL1B) release. DPP9 activity is modulated by upstream signals including EGF, TGFB1, and HIF1A, and its protease function intersects with protein degradation pathways and cell adhesion dynamics. In the context of NCI-H1975 cells, DPP9-mediated NLRP1 suppression may interact with EGFR/MAPK signaling components such as ERK1/2, linking proteolytic homeostasis to survival and motility pathways.
Loss of DPP9 in NCI-H1975 cells is predicted to de-repress the NLRP1 inflammasome, leading to spontaneous CASP1 activation and IL1B secretion. This pro-inflammatory state can alter cell adhesion, migration, and apoptotic thresholds, potentially impacting epithelial-mesenchymal transition (EMT) and tumor microenvironment crosstalk. The EGFR/T790M-driven background of the host line makes this knockout model especially valuable for dissecting whether DPP9 loss contributes to TKI resistance or metastatic progression. By combining inflammasome dysregulation with EGFR pathway activity, researchers can examine novel intersections between innate immune signaling and oncogenic survival networks.
Typical research applications for these polyclonal knockout cells include detailed investigation of DPP9??s role in NLRP1 inflammasome regulation using caspase-1 activity assays and IL-1?? ELISA to quantify inflammasome output, studying EGFR-TKI resistance mechanisms via cell viability assays and phospho-EGFR signaling arrays to map pathway alterations, and exploring tumor microenvironment interactions through migration/invasion assays and immunofluorescence detection of inflammasome puncta formation. The model also supports RT-qPCR and western blotting for DPP9, NLRP1, and downstream targets, enabling multilayered analyses of gene and protein expression changes. For further information or technical support, please contact Ascent Research.
